June 30, 2022

Medical Trend

Medical News and Medical Resources

This “psychedelic mushroom” can actually treat depression

This “psychedelic mushroom” can actually treat depression



 

Clinical trials have confirmed that this “psychedelic mushroom” can actually treat depression, and the effect is remarkable.

When it comes to mushrooms , believe most people will immediately think of delicious food. However, not all mushrooms are non-toxic and edible, and there are not a few people who are admitted to the hospital for eating toxic wild mushrooms every year.

Not only that, some mushrooms also contain hallucinogenic toxins, which make people produce colorful and dreamlike hallucinations.

 

Magic mushrooms is such a hallucinogenic mushrooms, magic mushrooms is psilocybin (psilocybin) occurs within a few hours after ingestion of the machine experience to produce visual hallucinations, and profound changes in people’s consciousness, It will make people see some fantasy scenes-distorted space, colorful bubbles, and even some magical animals that do not exist in reality.

But it needs to be emphasized that psychedelic mushrooms are actually a soft drug. In the UK, psychedelic mushrooms are even classified as Class A illegal drugs.

 

On November 9, 2021, Compass Pathways issued a statement, announcing the results of the largest ever clinical trial of psilocybin in the treatment of major depression.

The results of the Phase 2b clinical trial involving 233 patients with major depression showed that, 29.1% of the patients in the high-dose group were effectively relieved of their depression 3 weeks after treatment, and continued to relieve for several months, compared with only 7.6% in the control group.

 

Lars Christian Wilde , co-founder and president of Compass Pathways , said that this treatment effect has never been seen in previous depression studies, and this result is very satisfactory.

 

Major depressive disorder (MDD)affects more than 300 million people worldwide and is a major public health problem. In the United States alone, approximately 10% of adults were diagnosed with major depression last year. At the same time, the annual economic burden of major depression is estimated to be as high as 210 billion US dollars.

 

More importantly, the current drugs used to treat depression are very limited and often have serious side effects .

Therefore, considering the serious negative impact of major depression on public health, humans need to develop more drugs with rapid and sustained antidepressant effects.

 

Psilocybin (psilocybin) shows joint activity with common depression treatment drugs (serotonergic and glutaminergic drugs) .

In addition, with the new class of drugs chloramines – compared to ketamine, psilocybin (psilocybin) having addiction and toxic effects lower , and is often associated with long-term perception, cognitive or neurological dysfunction does not matter.

 

Prior to this, November 4 2020, researchers at Johns Hopkins University School of Medicine in JAMA sub-Journal JAMA Psychiatry published a report entitled on: Effects of Psilocybin-Assisted Therapy ON Major Depressive DisorderA Randomized Clinical Trial Clinical Test thesis.

 

The new clinical study shows that the active chemical components magic mushrooms – psilocybin (psilocybin) can effectively improve major depressive disorder (MDD) symptoms, and has a fast response, efficacy and side effects lasting benefits expected Become a new generation of long-acting depression drugs !

 

This "psychedelic mushroom" can actually treat depression

 

In this regard , Dr. Alan Davis , the first author of the research paper , said: “ New antidepressants have a rapid and lasting effect on mood and cognition. This may be a breakthrough in the treatment of depression and may improve or save more. Life .”

 

The results of the largest clinical trial of psilocybin in the treatment of depression announced by Compass Pathways this time further confirms the great potential of psilocybin for the treatment of depression.

 

The results of this clinical trial have not yet been published, and the specific details are not yet known. However , the data released by Compass Pathways showed that a small number of patients had side effects.

Specifically, 5 patients in the 25 mg dose group, 6 patients in the 10 mg dose group, and 1 patient Serious side effects occurred in the milligram dose group, including suicide and self-harm.

But the company also said that suicide and self-harm is not uncommon for patients with major depression.

 

 

Reference:
https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2772630
https://www.statnews.com/2021/11/09/largest-psilocybin-trial-finds-psychedelic-effective-treating-serious-depression/

 

(source:internet, reference only)


Disclaimer of medicaltrend.org